Areteia Therapeutics

Executive Summary

Areteia Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing dexpramipexole, a novel oral small molecule that lowers eosinophil levels, for the treatment of eosinophilic esophagitis (EoE) and other eosinophil-driven diseases. Founded in 2022 and headquartered in Durham, NC, the company has raised $75 million and is advancing its lead asset through Phase 3 trials for EoE, with a Phase 2 study underway in severe asthma. Dexpramipexole’s oral administration and disease-modifying potential position it as a promising alternative to current therapies, which often require invasive procedures or chronic steroid use. The company’s primary catalyst is the topline data readout from its pivotal Phase 3 trial in EoE, expected in late 2026. Positive results could support a New Drug Application (NDA) submission and validate the drug’s broader applicability in eosinophilic disorders. Additionally, interim data from the Phase 2 asthma study is anticipated in early 2027, offering further proof-of-concept. With a strong mechanistic rationale and a clear regulatory pathway, Areteia Therapeutics represents a compelling high-risk, high-reward opportunity in the respiratory and immunology space.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Topline Data for Eosinophilic Esophagitis65% success
• Q1 2027Phase 2 Topline Data for Severe Asthma55% success